FindTrial
Sign In

Comparative Study of Therapeutic Efficacy and Safety of Glycolic Acid 6% and Azelaic Acid 20% in Melasma

PROSPECTIVE RANDOMIZED COMPARATIVE STUDY OF THERAPEUTIC EFFICACY AND SAFETY OF GLYCOLIC ACID 6% AND AZELAIC ACID 20% IN MELASMA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/06/034044
Enrollment
60
Registered
2021-06-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L814- Other melanin hyperpigmentation

Interventions

Intervention1: Treatment of melasma: Comparing two drugs in the treatment of melasma Control Intervention1: Azelaic Acid 20% and Glycolic Acid 6%: Dosage depends on degree of melasma usually expressed

Sponsors

ARULVASAN S S
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient with clinical diagnosis of facial melasma

Exclusion criteria

Exclusion criteria: Patients who are non compliance, pregnant, lactating mothers. Patients who had already undergone other melasma treatment within 6 months. Patient with known allergy to azelaic acid or glycolic acid

Design outcomes

Primary

MeasureTime frame
Clinical improvement in facial melasmaTimepoint: at baseline , 4 weeks and 8weeks—

Secondary

MeasureTime frame
Improvement in MASI scoreTimepoint: To less than 10%—

Countries

India

Contacts

Public ContactARULVASAN S S

VINAYAGA MISSION MEDICAL COLLEGE, KARAIKAL

shivam1957.ss@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026